GlassScriptPhysician profile
Christina L Michaelis
NPI 1134338221
$9,306.45
in general payments reported to CMS, 2019-2025
60 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $1,064 · 2021: $1,834 · 2022: $1,656 · 2023: $943 · 2024: $722 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.45 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $971.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $870.79 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $665.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $566.21 | 2019-2022 | |
| Abbott Laboratories | $520.88 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $510.98 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $406.24 | 2021-2023 | Afrezza |
| Lilly USA, LLC | $389.02 | 2019-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $359.25 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $315.12 | 2019-2025 | |
| Cequr Corporation | $314.57 | 2021-2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $307.85 | 2024-2025 | |
| Valeritas, INC. | $288.75 | 2019 | |
| Zealand Pharma US, INC. | $232.08 | 2020-2022 | |
| Corcept Therapeutics | $227.22 | 2020-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Michaelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.